Disitamab vedotin
As of the edition of 20 October 2026, Disitamab vedotin is an antibody drug conjugate: in active development; acts on ERBB2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2029
- Kind
- Antibody drug conjugate
- Registered trials
- 96, 1 stopped early
- Disease areas
- Cancer; Digestive system; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | P04626 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 1 | 4 | 0 |
| Phase 1 | 3 | 0 | 2 | 0 |
| Phase 2 | 71 | 1 | 50 | 1 |
| Phase 3 | 12 | 0 | 12 | 0 |
| Phase 4 | 4 | 0 | 0 | 0 |
| All trials | 96 |